Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and
surrounding tissue, thus making these pathogens substantially more susceptible to established
antibiotic treatment regimens. This initial study is designed to assess overall safety and
pharmacokinetics (PK) of TRL1068. The overall goal of the development program is to
demonstrate that TRL1068 can facilitate effectiveness of a single stage joint replacement or
preservation of the original infected prosthetic joint in a substantial proportion of
patients with PJI.
Phase:
Phase 1
Details
Lead Sponsor:
Trellis Bioscience LLC
Collaborators:
Biomedical Advanced Research and Development Authority Sinai Hospital of Baltimore University of California, Los Angeles Wellcome Trust